Malignant Pleural Mesothelioma: An Update on the Role of Surgery

Maria Kalliopi Konstantinidou; Christos Kakos; Dimitrios Kyparissopoulos

doi:doi:10.11648/j.ijcts.20170306.14

| Peer-Reviewed

Malignant Pleural Mesothelioma: An Update on the Role of Surgery

Maria Kalliopi Konstantinidou, Christos Kakos, Dimitrios Kyparissopoulos

Published in International Journal of Cardiovascular and Thoracic Surgery (Volume 3, Issue 6)

Received: 29 October 2017 Accepted: 4 December 2017 Published: 26 December 2017

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Mesothelioma is a rare type of cancer which can occur in various sites, such as the peritoneum, the pericardium and tunica vaginalis testis; but malignant pleural mesothelioma is the most common type. Malignant pleural mesothelioma commonly affects older males that have been exposed to asbestos 20-40 years ago. The disease is difficult to be treated and has an overall survival expectancy of about 1 year. Histological subtypes include epithelioid, sarcomatoid and biphasic or mixed. Diagnosing this type of cancer is rather challenging and as a result it is usually diagnosed in most patients in progressed stages. Surgery with minimal procedures is applied to reach the diagnosis, with the Video Assisted Thoracoscopic procedure being considered to be the “gold standard”. Patients with malignant pleural mesothelioma should be managed by experienced multidisciplinary teams, as treatment options include surgery, radiation therapy and /or chemotherapy. Extrapleural pneumonectomy and pleurectomy/decortication are the preferred procedures in the treatment of this malignancy, but whether they prolong life expectancy or improve quality of life of the patients still remains a controversial issue. In any case, careful assessment before surgery is of paramount importance. Multimodality approaches, which include surgery for patients who are fit, are often chosen in order to increase survival rates in clinical trials.

Published in	International Journal of Cardiovascular and Thoracic Surgery (Volume 3, Issue 6)
DOI	10.11648/j.ijcts.20170306.14
Page(s)	78-85
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2017. Published by Science Publishing Group

Keywords

Malignant Pleural Mesothelioma, Pleurectomy, Extra-Pleural Pneumonectomy, Surgery, Review

References

[1]	P. Baas, D. Fennell, K. M. Kerr, P. E. Van Schil, R. L. Haas & S. Peters, on behalf of the ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep; 26 Suppl 5:v31-9. doi: 10.1093/annonc/mdv199. Epub 2015 Jul 28.
[2]	Asbestos: elimination of asbestos-related diseases. Fact sheet N°343 World Health Organisation, 2016. Available online: http://www.who.int/mediacentre/factsheets/fs343/en/index.html.
[3]	Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17: 260–271.
[4]	Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591–1603. doi:10.1056/NEJMra050152.
[5]	Jing Ai and James P. Stevenson Current Issues in Malignant Pleural Mesothelioma Evaluation and Management Oncologist. 2014 Sep; 19 (9): 975–984. doi: 10.1634/theoncologist.2014-0122.
[6]	A. Scherpereel, P. Astoul, P. Baas, T. Berghmans, H. Clayson, P. de Vuyst, et al. ERS/ESTS TASK FORCE. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir. J. 2010; 35: 479-495 doi: 10.1183/09031936.00063109.
[7]	M. T. Truong, C. Viswanathan, MB. C. Godoy, Brett W. Carter, EM. Marom. Malignant Pleural Mesothelioma: Role of CT, MRI, and PET/CT in Staging Evaluation and Treatment Considerations doi: 10.1053/j.ro.2013.03.017.
[8]	Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, et al, Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J Clin Oncol 2007; 25: 1489–1497.
[9]	Roushdy-Hammady I, Siegel J, Emri S, et al. Genetic susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001; 357: 444–445 doi: http://dx.doi.org/10.1016/S0140-6736 (00)04922-9.
[10]	K. Sakellariou, V. Malamou-Mitsi, A. Haritou, C. Koumpaniou, C. Stachouli, I. D. Dimoliatis, S. H. Constantopoulos. Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic? Eur Respir J., 1996, 9, 1206–1210.
[11]	Cristaudo A, Foddis R, Vivaldi A, et al. SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res 2005; 65: 3049–3052.
[12]	Manfredi JJ, Dong J, Liu WJ, et al. Evidence against a role for SV40 in human mesothelioma. Cancer Res 2005; 65: 2602–2609.
[13]	M. Ray, H. L. Kindler. Malignant pleural mesothelioma. An Update on Biomarkers and Treatment. Chest 2009; 136: 888–896 doi: 10.1378/chest.08-2665.
[14]	Shivani C Patel and Jonathan E Dowell Modern management of malignant pleural mesothelioma. Lung Cancer (Auckl). 2016; 7: 63–72. doi: 10.2147/LCTT. S83338.
[15]	Ordonez NG Immunohistochemical Diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005; 129: 1407-1414.
[16]	Kouki Inai Pathology of mesothelioma Environ Health Prev Med. 2008 Mar; 13 (2): 60–64. doi: 10.1007/s12199-007-0017-6.
[17]	Luigina Micolucci, Most Mauluda Akhtar, Fabiola Olivieri, Maria Rita Rippo, and Antonio Domenico Procopio Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis Oncotarget. 2016 Sep 6; 7 (36): 58606–58637. doi: 10.18632/oncotarget.9686.
[18]	Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16: 145–152.
[19]	Opitz I, Friess M, Kestenholz P, Schneiter D, Frauenfelder T, Nguyen-Kim TD, et al. A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience. J Thorac Oncol. 2015 Nov; 10 (11): 1634-41 doi: 10.1097/JTO.0000000000000661.
[20]	Pilling J, Dartnell JA, Lang- Lazdunski L. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic diseaseof patients undergoing trimodality therapy for malignant pleural mesothelioma. Thorac Cardiovas Surg 2010; 58: 215-219.
[21]	Rice DC, Steliga MA, Stewart J, et al. Endoscopic ultrasound guided fine needle aspiration for staging of malignant pleural mesothelioma. Ann Thorac Surg 2009; 88: 862-869. doi: 10.1016/j.athoracsur.2009.05.022.
[22]	Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual, 7th edition. New York: Springer; 2010.
[23]	Wilcox BE, Supramaniam RM, Paller PJ, et al. Utility of integrated computed tomography- positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer 2009; 10: 244-248 doi: 10.3816/CLC.2009.n.033.
[24]	Aelony Y, Yao JF. Prolonged survival after talk poudrage for malignant pleural mesothelioma: case series. Respirology 2005; 10: 649-655.
[25]	Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J, et al. Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma. A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group Journal of Thoracic Oncology, VOL 6, Number 8, August 2011 doi: 10.1097/JTO.0b013e3182208e3f.
[26]	Waller DA, Morritt GN, Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest 1995; 107: 1454–1456.
[27]	Soysal O, Karaoglanoglu N, Demiracan S, et al. Pleurectomy/ decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur J Cardiothorac Surg 1997; 11: 210–213.
[28]	J C Halstead 1, E Lim, R M Venkateswaran, S C Charman, M Goddard, A J Ritchie. Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma. Eur J Surg Oncol 2005; 31: 314–320. doi: 10.1016/j.ejso.2004.08.014.
[29]	Apostolos Nakas 1, Antonio E Martin Ucar, John G Edwards, David A Waller. The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2008; 33: 83–88. doi: 10.1016/j.ejcts.2007.09.039.
[30]	Martin-Ucar AE, Edwards JG, Rengajaran A, et al. Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. Eur J Cardiothorac Surg 2001; 20: 1117–1121.
[31]	Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, et al, MesoVATS Collaborators. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014 Sep 20; 384 (9948): 1118-27. doi: 10.1016/S0140-6736 (14)60418-9.
[32]	Cao C, Tian DH, Pataky KA, Yan TD Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma. Lung Cancer. 2013 Sep; 81 (3): 319-27 doi: 10.1016/j.lungcan.2013.04.024.
[33]	Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD, A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014 Feb; 83 (2): 240-5 doi: 10.1016/j.lungcan.2013.11.026
[34]	Spaggiari L, Marulli G, Bovolato P, Alloisio M, Pagan V, Oliaro A, et al. Extrapleural Pneumonectomy for Malignant Mesothelioma: An Italian Multicenter Retrospective Study Ann Thorac Surg. 2014 Jun; 97 (6): 1859-65 doi: 10.1016/j.athoracsur.2014.01.050.
[35]	Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004; 128: 138–146. doi: 10.1016/j.jtcvs.2004.02.021.
[36]	Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 122: 788–795. doi: 10.1067/mtc.2001.116560.
[37]	Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18: 1196–1202. doi: 10.1093/annonc/mdm093.
[38]	Wolf AS, Flores RM. Current Treatment of Mesothelioma: Extrapleural Pneumonectomy Versus Pleurectomy/Decortication. Thorac Surg Clin. 2016 Aug; 26 (3): 359-75 doi: 10.1016/j.thorsurg.2016.04.003.
[39]	Taioli E, Wolf AS, Flores RM Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg. 2015 Feb; 99 (2): 472-80 doi: 10.1016/j.athoracsur.2014.09.056.
[40]	MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma (MARS2) NCT02040272. https://clinicaltrials.gov/ct2/show/NCT02040272 Date last updated: May 11, 2017. Date last accessed: May 2017.
[41]	Wald O, Sugarbaker DJ. Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient. J Thorac Dis. 2017; 9 (3): 485–489. doi:10.21037/jtd.2017.03.27.
[42]	Flores RM, Pass H, Seshan VE, Dycoco J, Zakowski M, Carbone M, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008; 135: 620–626 doi: 10.1016/j.jtcvs.2007.10.054.
[43]	Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 7: 1196–1202 doi: 10.1093/annonc/mdm093.
[44]	Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 3007–3013 doi: 10.1200/JCO.2008.20.3943.
[45]	Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al; MARS trialists. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011 Aug; 12 (8): 763-72. doi: 10.1016/S1470-2045 (11)70149-8.
[46]	Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol. 2011 Nov; 12 (12): 1093-4. doi: 10.1016/S1470-2045 (11)70307-2.
[47]	Yan TD, Cao CQ, Boyer M et al. Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience. Ann Thorac Cardiovasc Surg 2011; 17: 243-249.
[48]	Zauderer MG, Krug LM. The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol 2011; 12: 163-172 doi: 10.1007/s11864-011-0146-4.
[49]	Cao C, Tian D, Manganas C et al. Systematic review of trimodality therapy for patients with malignant pleural mesothelioma. Ann Cardiothorac Surg 2012; 1: 428 – 437. doi: 10.3978/j.issn.2225-319X.2012.11.07.
[50]	Davies HE, Musk AW, Lee YC. Prophyllactic radiotherapy for pleural puncture sites: the controversy continues. Curr Opin Pulm Med 2008; 14: 326–330 doi: 10.1097/MCP.0b013e3282fcea50.
[51]	Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015 Dec; 16 (16): 1651-8. doi: 10.1016/S1470-2045 (15)00208-9.
[52]	Clive AO, Taylor H, Dobson L, Wilson P, de Winton E, Panakis N, Pepperell J, Howell T, Stewart SA, Penz E, Jordan N, Morley AJ, Zahan-Evans N, Smith S, Batchelor TJ, Marchbank A, Bishop L, Ionescu AA, Bayne M, Cooper S, Kerry A, Jenkins P, Toy E, Vigneswaran V, Gildersleve J, Ahmed M, McDonald F, Button M, Lewanski C, Comins C, Dakshinamoorthy M, Lee YC, Rahman NM, Maskell NA Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016 Aug; 17 (8): 1094-104. doi: 10.1016/S1470-2045 (16)30095-X.

Cite This Article

Plain Text BibTeX RIS

APA Style

Maria Kalliopi Konstantinidou, Christos Kakos, Dimitrios Kyparissopoulos. (2017). Malignant Pleural Mesothelioma: An Update on the Role of Surgery. International Journal of Cardiovascular and Thoracic Surgery, 3(6), 78-85. https://doi.org/10.11648/j.ijcts.20170306.14

Copy | Download

ACS Style

Maria Kalliopi Konstantinidou; Christos Kakos; Dimitrios Kyparissopoulos. Malignant Pleural Mesothelioma: An Update on the Role of Surgery. Int. J. Cardiovasc. Thorac. Surg. 2017, 3(6), 78-85. doi: 10.11648/j.ijcts.20170306.14

Copy | Download

AMA Style

Maria Kalliopi Konstantinidou, Christos Kakos, Dimitrios Kyparissopoulos. Malignant Pleural Mesothelioma: An Update on the Role of Surgery. Int J Cardiovasc Thorac Surg. 2017;3(6):78-85. doi: 10.11648/j.ijcts.20170306.14

Copy | Download

@article{10.11648/j.ijcts.20170306.14,
  author = {Maria Kalliopi Konstantinidou and Christos Kakos and Dimitrios Kyparissopoulos},
  title = {Malignant Pleural Mesothelioma: An Update on the Role of Surgery},
  journal = {International Journal of Cardiovascular and Thoracic Surgery},
  volume = {3},
  number = {6},
  pages = {78-85},
  doi = {10.11648/j.ijcts.20170306.14},
  url = {https://doi.org/10.11648/j.ijcts.20170306.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcts.20170306.14},
  abstract = {Mesothelioma is a rare type of cancer which can occur in various sites, such as the peritoneum, the pericardium and tunica vaginalis testis; but malignant pleural mesothelioma is the most common type. Malignant pleural mesothelioma commonly affects older males that have been exposed to asbestos 20-40 years ago. The disease is difficult to be treated and has an overall survival expectancy of about 1 year. Histological subtypes include epithelioid, sarcomatoid and biphasic or mixed. Diagnosing this type of cancer is rather challenging and as a result it is usually diagnosed in most patients in progressed stages. Surgery with minimal procedures is applied to reach the diagnosis, with the Video Assisted Thoracoscopic procedure being considered to be the “gold standard”. Patients with malignant pleural mesothelioma should be managed by experienced multidisciplinary teams, as treatment options include surgery, radiation therapy and /or chemotherapy. Extrapleural pneumonectomy and pleurectomy/decortication are the preferred procedures in the treatment of this malignancy, but whether they prolong life expectancy or improve quality of life of the patients still remains a controversial issue. In any case, careful assessment before surgery is of paramount importance. Multimodality approaches, which include surgery for patients who are fit, are often chosen in order to increase survival rates in clinical trials.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - Malignant Pleural Mesothelioma: An Update on the Role of Surgery
AU  - Maria Kalliopi Konstantinidou
AU  - Christos Kakos
AU  - Dimitrios Kyparissopoulos
Y1  - 2017/12/26
PY  - 2017
N1  - https://doi.org/10.11648/j.ijcts.20170306.14
DO  - 10.11648/j.ijcts.20170306.14
T2  - International Journal of Cardiovascular and Thoracic Surgery
JF  - International Journal of Cardiovascular and Thoracic Surgery
JO  - International Journal of Cardiovascular and Thoracic Surgery
SP  - 78
EP  - 85
PB  - Science Publishing Group
SN  - 2575-4882
UR  - https://doi.org/10.11648/j.ijcts.20170306.14
AB  - Mesothelioma is a rare type of cancer which can occur in various sites, such as the peritoneum, the pericardium and tunica vaginalis testis; but malignant pleural mesothelioma is the most common type. Malignant pleural mesothelioma commonly affects older males that have been exposed to asbestos 20-40 years ago. The disease is difficult to be treated and has an overall survival expectancy of about 1 year. Histological subtypes include epithelioid, sarcomatoid and biphasic or mixed. Diagnosing this type of cancer is rather challenging and as a result it is usually diagnosed in most patients in progressed stages. Surgery with minimal procedures is applied to reach the diagnosis, with the Video Assisted Thoracoscopic procedure being considered to be the “gold standard”. Patients with malignant pleural mesothelioma should be managed by experienced multidisciplinary teams, as treatment options include surgery, radiation therapy and /or chemotherapy. Extrapleural pneumonectomy and pleurectomy/decortication are the preferred procedures in the treatment of this malignancy, but whether they prolong life expectancy or improve quality of life of the patients still remains a controversial issue. In any case, careful assessment before surgery is of paramount importance. Multimodality approaches, which include surgery for patients who are fit, are often chosen in order to increase survival rates in clinical trials.
VL  - 3
IS  - 6
ER  -

Copy | Download

Author Information

Maria Kalliopi Konstantinidou

Department of Cardiothoracic Surgery, Harefield Hospital, London, UK
Christos Kakos

Department of Cardiothoracic Surgery, Harefield Hospital, London, UK
Dimitrios Kyparissopoulos

Department of Thoracic Surgery, Mediterranean Hospital of Cyprus, Limassol, Cyprus

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Maria Kalliopi Konstantinidou, Christos Kakos, Dimitrios Kyparissopoulos. (2017). Malignant Pleural Mesothelioma: An Update on the Role of Surgery. International Journal of Cardiovascular and Thoracic Surgery, 3(6), 78-85. https://doi.org/10.11648/j.ijcts.20170306.14

Copy | Download

ACS Style

Maria Kalliopi Konstantinidou; Christos Kakos; Dimitrios Kyparissopoulos. Malignant Pleural Mesothelioma: An Update on the Role of Surgery. Int. J. Cardiovasc. Thorac. Surg. 2017, 3(6), 78-85. doi: 10.11648/j.ijcts.20170306.14

Copy | Download

AMA Style

Maria Kalliopi Konstantinidou, Christos Kakos, Dimitrios Kyparissopoulos. Malignant Pleural Mesothelioma: An Update on the Role of Surgery. Int J Cardiovasc Thorac Surg. 2017;3(6):78-85. doi: 10.11648/j.ijcts.20170306.14

Copy | Download

@article{10.11648/j.ijcts.20170306.14,
  author = {Maria Kalliopi Konstantinidou and Christos Kakos and Dimitrios Kyparissopoulos},
  title = {Malignant Pleural Mesothelioma: An Update on the Role of Surgery},
  journal = {International Journal of Cardiovascular and Thoracic Surgery},
  volume = {3},
  number = {6},
  pages = {78-85},
  doi = {10.11648/j.ijcts.20170306.14},
  url = {https://doi.org/10.11648/j.ijcts.20170306.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcts.20170306.14},
  abstract = {Mesothelioma is a rare type of cancer which can occur in various sites, such as the peritoneum, the pericardium and tunica vaginalis testis; but malignant pleural mesothelioma is the most common type. Malignant pleural mesothelioma commonly affects older males that have been exposed to asbestos 20-40 years ago. The disease is difficult to be treated and has an overall survival expectancy of about 1 year. Histological subtypes include epithelioid, sarcomatoid and biphasic or mixed. Diagnosing this type of cancer is rather challenging and as a result it is usually diagnosed in most patients in progressed stages. Surgery with minimal procedures is applied to reach the diagnosis, with the Video Assisted Thoracoscopic procedure being considered to be the “gold standard”. Patients with malignant pleural mesothelioma should be managed by experienced multidisciplinary teams, as treatment options include surgery, radiation therapy and /or chemotherapy. Extrapleural pneumonectomy and pleurectomy/decortication are the preferred procedures in the treatment of this malignancy, but whether they prolong life expectancy or improve quality of life of the patients still remains a controversial issue. In any case, careful assessment before surgery is of paramount importance. Multimodality approaches, which include surgery for patients who are fit, are often chosen in order to increase survival rates in clinical trials.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - Malignant Pleural Mesothelioma: An Update on the Role of Surgery
AU  - Maria Kalliopi Konstantinidou
AU  - Christos Kakos
AU  - Dimitrios Kyparissopoulos
Y1  - 2017/12/26
PY  - 2017
N1  - https://doi.org/10.11648/j.ijcts.20170306.14
DO  - 10.11648/j.ijcts.20170306.14
T2  - International Journal of Cardiovascular and Thoracic Surgery
JF  - International Journal of Cardiovascular and Thoracic Surgery
JO  - International Journal of Cardiovascular and Thoracic Surgery
SP  - 78
EP  - 85
PB  - Science Publishing Group
SN  - 2575-4882
UR  - https://doi.org/10.11648/j.ijcts.20170306.14
AB  - Mesothelioma is a rare type of cancer which can occur in various sites, such as the peritoneum, the pericardium and tunica vaginalis testis; but malignant pleural mesothelioma is the most common type. Malignant pleural mesothelioma commonly affects older males that have been exposed to asbestos 20-40 years ago. The disease is difficult to be treated and has an overall survival expectancy of about 1 year. Histological subtypes include epithelioid, sarcomatoid and biphasic or mixed. Diagnosing this type of cancer is rather challenging and as a result it is usually diagnosed in most patients in progressed stages. Surgery with minimal procedures is applied to reach the diagnosis, with the Video Assisted Thoracoscopic procedure being considered to be the “gold standard”. Patients with malignant pleural mesothelioma should be managed by experienced multidisciplinary teams, as treatment options include surgery, radiation therapy and /or chemotherapy. Extrapleural pneumonectomy and pleurectomy/decortication are the preferred procedures in the treatment of this malignancy, but whether they prolong life expectancy or improve quality of life of the patients still remains a controversial issue. In any case, careful assessment before surgery is of paramount importance. Multimodality approaches, which include surgery for patients who are fit, are often chosen in order to increase survival rates in clinical trials.
VL  - 3
IS  - 6
ER  -

Copy | Download